Bispecific Nanobody‐Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors
Small · 2024
DOI: 10.1002/smll.202308265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Ya Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Materials, University of Science and Technology of China, Hefei, 230026, China. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Single-Domain Antibodies, Neoplasms, Antibodies, Bispecific. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Zhejiang Leading Innovation and Entrepreneurship Team, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Bispecific antibodies possess exceptional potential as therapeutic agents due to their capacity to bind to two different antigens simultaneously. However, challenges pertain to unsatisfactory stability, manufacturing complexity, and limited tumor penetration hinder their broad applicability. In this study, a versatile technology is presented for the rapid generation of bispecific nanobody‐aptamer conjugates with efficient tumor penetration. The approach utilizes microbial transglutaminase (MTGase) and click chemistry to achieve site‐specific conjugation of nanobodies and aptamers, which are termed nanotamers. The nanotamers recognize and bind to two types of molecular targets expressed on cancer cells. As a prototype, a bispecific nanotamer is developed that binds both clusters of differentiation 47 (CD47) and mesenchymal epithelial transition receptor (Met) expressed on the tumor cell membrane. This CD47‐Met nanotamer demonstrates high affinity and specificity toward tumor cells expressing both targets, exhibits improved receptor functional inhibition through a strong steric hindrance effect. Moreover, its capacity for deep tumor penetration greatly enhances the impact of conventional chemotherapy on antitumor efficacy. The as‐developed nanotamer synthesis approach shows promise to customize bispecific molecular probes targeting different cancer types and different therapeutic goals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Materials, University of Science and Technology of China, Hefei, 230026, China.
- Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
- School of Pharmacy, Nantong University, Nantong, 226019, China.
ORCID-Profile: Juan Li
Förderung
- Zhejiang Leading Innovation and Entrepreneurship Team
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, Y., Chen, J., Zhang, S., Jiang, H., Zhu, J., Jiang, G., Liu, Y., Zhu, Y., & Li, J. (2024). Bispecific Nanobody‐Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors. Small. https://doi.org/10.1002/smll.202308265
Vancouver
Wang Y, Chen J, Zhang S, Jiang H, Zhu J, Jiang G, et al. Bispecific Nanobody‐Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors. Small. 2024. doi:10.1002/smll.202308265
BibTeX
@article{Wang2024,
author = {Wang, Ya and Chen, Jie and Zhang, Sen and Jiang, Hang and Zhu, Jianqing and Jiang, Guangyi and Liu, Yichang and Zhu, Yingdi and Li, Juan},
title = {Bispecific Nanobody‐Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202308265}
}
EUVIMED